52605-97-7

Usage

Chemical Properties

Yellow Liquid

Uses

2,3-Dimethoxypyridine (cas# 52605-97-7) is a compound useful in organic synthesis.

InChI:InChI=1/C7H9NO2/c1-9-6-4-3-5-8-7(6)10-2/h3-5H,1-2H3

Upstream product

• 67-56-1 methanol 
• 52605-96-6 2-chloro-3-methoxypyridine 
• 109-09-1 2-chloropyridine 
• 6636-78-8 2-chloro-3-hydroxypyridine 
• 124-41-4 sodium methylate 
• 24100-18-3 2-bromo-3-methoxypyridine 
• 2402-77-9 2,3-dichloro-pyridine 

Downstream Products

• 52605-98-8 5-bromo-2,3-dimethoxypyridine 
• 1031438-93-3 (2,3-dimethoxypyridin-4-yl)boronic acid 
• 52606-08-3 6-bromo-2,3-dimethoxypyridine 

Relevant academic research and scientific papers

D-AMINO ACID OXIDASE INHIBITORS AND THERAPEUTIC USES THEREOF

The present invention relates to compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein: each of A, B, C, D, and E, independently, is C, N, N—H, O, S, or absent is a single bond or a double bond; each of X, Y, and Z, independentl

Synthetic method of 2,5,6-trimethoxy-3-picolinic acid

The invention relates to a synthetic method of 2,5,6-trimethoxy-3-picolinic acid, which mainly solves the technical problem that no effective synthetic methods are provided at present. The synthetic method provided by the invention comprises the following steps: converting 2-chloro-3-hydroxypyridine hydroxy into methoxy; carrying out methoxy nucleophilic substitution of chlorine; carrying out bromination of a pyridine ring; and carrying out methoxy selective substitution of bromine; removing bromine from n-butyllithium, reacting with carbon dioxide, and introducing carboxy so as to obtain 2,5,6-trimethoxy-3-picolinic acid. In the whole synthetic process, intermediates and object products do not need to be separated through a chromatographic column, the raw materials are cheap, and the purification is simple.

FSH RECEPTOR ANTAGONISTS

The invention relates to FSH receptor antagonist according to general formula (I) or a pharmaceutically acceptable salt thereof and to a pharmaceutical composition containing the same. The compounds can be used for the treatment and prevention of endometriosis, for the treatment and prevention of pre-menopausal and peri-menopausal hormone-dependent breast cancer, for contraception, and for the treatment of uterine fibroids and other menstrual-related disorders

Camptothecin-analog with a novel, "flipped" lactone-stable, E-ring and methods for making and using same

The present invention discloses: (i) a novel, lactone-stable, “flipped” E-ring camptothecin, pharmaceutically-acceptable salts, and/or analogs thereof; (ii) methods of synthesis of said novel, lactone-stable, “flipped” E-ring camptothecin, pharmaceutically-acceptable salts, and/or analogs thereof; (iii) pharmaceutically-acceptable formulations comprising said novel, lactone-stable, “flipped” E-ring camptothecin, pharmaceutically-acceptable salts, and/or analogs thereof, and, optionally, one or more additional chemotherapeutic agents; (iv) methods of administration of said novel, lactone-stable, “flipped” E-ring camptothecin, pharmaceutically-acceptable salts, and/or analogs thereof, and, optionally, one or more additional chemotherapeutic agents, to subjects in need thereof; and (v) devices for the administration of said novel, lactone-stable, “flipped” E-ring camptothecin, pharmaceutically-acceptable salts, and/or analogs thereof, and, optionally, one or more chemotherapeutic agents, to subjects in need thereof.

CAMPTOTHECIN-ANALOG WITH A NOVEL, “FLIPPED” LACTONE-STABLE, E-RING AND METHODS FOR MAKING AND USING SAME

The present invention discloses: (i) a novel, lactone-stable, “flipped” E-ring camptothecin, pharmaceutically-acceptable salts, and/or analogs thereof; (ii) methods of synthesis of said novel, lactone-stable, “flipped” E-ring camptothecin, pharmaceutically-acceptable salts, and/or analogs thereof; (iii) pharmaceutically-acceptable formulations comprising said novel, lactone-stable, “flipped” E-ring camptothecin, pharmaceutically-acceptable salts, and/or analogs thereof, and, optionally, one or more additional chemotherapeutic agents; (iv) methods of administration of said novel, lactone-stable, “flipped” E-ring camptothecin, pharmaceutically-acceptable salts, and/or analogs thereof, and, optionally, one or more additional chemotherapeutic agents, to subjects in need thereof; and (v) devices for the administration of said novel, lactone-stable, “flipped” E-ring camptothecin, pharmaceutically-acceptable salts, and/or analogs thereof, and, optionally, one or more chemotherapeutic agents, to subjects in need thereof.

Antitumor agents 222. Synthesis and anti-androgen activity of new diarylheptanoids

Fifteen new diarylheptanoids were synthesized and evaluated for antagonistic activity against androgen receptor (AR)-mediated reporter gene transcription using DU145, PC-3, and LNCaP prostate cancer cell lines. Most compounds showed activity in a 5α-dihydrotestosterone (DHT)-induced reporter gene expression assay in DU145 cells transfected with wild-type AR. Ten compounds (5, 8, 10, 14-15, and 18-22) were equipotent with hydroxyflutamide (HF), the anti-androgen currently available for the treatment of prostate cancer. However, except for compounds 5 and 10, none of the tested compounds was significantly effective in attenuating DHT-induced reporter gene expression in LNCaP cells, which contain endogenous mutant AR.

Total Synthesis of (+/-)-Atpenin B. An Original "Clockwise" Functionalization of 2-Chloropyridine

(-)-Atpenin B (1) is an antibiotic produced by Penicillim sp.FO-125.The first synthesis of 2,4-dihydroxy-5,6-dimethoxy-3-((2RS,4RS)-2,4-dimethyl-1-oxohexyl)pyridine (atpenin B) (16) is reported.This molecule, which exhibits a pentasubstituted pyridine structure, was prepared from 2-chloropyridine in 13 steps, by metalating and then functionalizing, one after another, all the remaining positions of the pyridine ring.The methodology involves four metalation steps (including metalation of 2,3-dimethoxypyridine and pyridyl N,N-diisopropylcarbamates), one halogen-scrambling step, and one bromine-lithium exchange step.

NEW REACTIONS OF PYRIDINES AND TOTAL SYNTHESIS OF THE FUNGAL TOXIN ORELLANINE

Dihalogenated pyridines react easily with sulphur nucleophiles, in dipolar aprotic solvents (DMF), to afford the products of mono- or of bis-substitution depending on the experimental conditions.On the contrary, with oxygen nucleophiles the bis-substituted products can be obtained only with some particular substrates.A new and efficient procedure to effect the homo-coupling of halogenoarenes will be presented.This reaction, wich occurs under the influence of low-valent nickel complexes, allowed us to effect the total synthesis of Orellanine, the lethal toxin of Cortinarius orellanus mushroom, as well as the syntheses of its decompositionproducts Orellinine and Orelline.The chemical properties of these three products and their behaviour towards UV irradiation will be presented and discussed.

THE REACTIONS OF SOME HALOGENATED PYRIDINES WITH METHOXYDE AND METHANETHIOLATE IONS IN DIMETHYLFORMAMIDE

The reactions of 2,6- and 2,5-dibromopyridines and of 2,3- and 3,5-dichloropyridines with sodium isopropanethiolate and methanethiolate afforded the products of mono- or of bis-substitution depending on the experimental conditions.The same pyridines reacted with sodium methoxide to give good yields of the mono-substituted products; bis-substitution occurred easily only in the case of the 2,6-dibromo- and of the 3,5-dichloropyridine.The syntheses of some methoxy thiomethoxypyridine, starting from the halogeno methoxypyridines or from the halogeno thiomethoxypyridines are also described.The bis-(alkylthio)pyridines can be fragmented by sodium in HMPA to give the bis(mercapto)pyridines.